STAAR Surgical Company (STAA)
Cash ratio
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 144,159 | 183,038 | 86,480 | 199,706 | 152,453 |
| Short-term investments | US$ in thousands | 86,335 | 37,688 | 125,159 | 0 | — |
| Total current liabilities | US$ in thousands | 70,306 | 65,036 | 51,716 | 48,802 | 41,236 |
| Cash ratio | 3.28 | 3.39 | 4.09 | 4.09 | 3.70 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($144,159K
+ $86,335K)
÷ $70,306K
= 3.28
The cash ratio of STAAR Surgical Company has shown a relatively stable trend over the past five years. The ratio was 3.70 as of December 31, 2020, and increased to 4.09 by the end of 2021. This level was maintained through the end of 2022.
However, there was a slight decline in the cash ratio to 3.39 as of December 31, 2023, and a further decrease to 3.28 by the end of 2024.
Overall, the company's cash ratio indicates that it has a healthy amount of cash and cash equivalents to cover its current liabilities. While the slight decrease in recent years may suggest some changes in the company's liquidity position, it is important to monitor this ratio closely to ensure the company has sufficient liquidity to meet its short-term obligations.
Peer comparison
Dec 31, 2024